Related Experiment Video

Updated: Aug 15, 2026

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation
11:49

Trans-vivo Delayed Type Hypersensitivity Assay for Antigen Specific Regulation

Published on: May 2, 2013

Early adequate mycophenolic acid exposure is associated with less rejection in kidney transplantation

Bryce A Kiberd1, Joseph Lawen, Albert D Fraser

  • 1Department of Medicine, Capital Health and Dalhousie University, Halifax, Nova Scotia, Canada. bkiberd@dal.ca

American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons
|June 16, 2004
PubMed

Insights

Early adequate exposure to mycophenolic acid (MPA) in kidney transplant patients predicts lower acute rejection rates. However, this early MPA exposure does not predict MMF toxicity, even with basiliximab induction therapy.

Area of Science:

  • Nephrology
  • Transplantation Immunology
  • Pharmacokinetics

Background:

  • Kidney transplantation requires immunosuppression to prevent rejection.
  • Mycophenolate mofetil (MMF) is a key immunosuppressant, metabolized to mycophenolic acid (MPA).
  • Optimizing MPA exposure is crucial for transplant success.

Purpose of the Study:

  • To investigate the association between early mycophenolic acid (MPA) exposure and clinical outcomes in kidney transplant recipients.
  • To determine if early MPA exposure predicts acute rejection or MMF toxicity.
  • To assess the role of MPA exposure in patients receiving basiliximab induction.

Main Methods:

  • Prospective evaluation of 94 first solitary kidney transplant patients.
  • Treatment regimen included cyclosporine, MMF, and prednisone; 72 patients received basiliximab.
  • MPA exposure measured by HPLC as 12-hour area under the curve (AUC [0-12]) within the first week post-transplant.
  • Efficacy assessed by acute rejection; toxicity by MMF dose reduction within 3 months.

Main Results:

  • Acute rejection occurred in 15% of patients; MMF toxicity in 29%.
  • MPA AUC [0-12] on day 3 predicted efficacy (c = 0.72, p = 0.007) but not toxicity (c = 0.57, p = 0.285).
  • In basiliximab-treated patients, day 3 MPA AUC [0-12] also predicted efficacy (c = 0.80, p = 0.01).

Conclusions:

  • Early adequate MPA exposure by day 3 is linked to reduced acute rejection in kidney transplant recipients.
  • Early MPA exposure does not reliably predict MMF toxicity.
  • Optimizing early MPA exposure is important, even with basiliximab induction therapy.

More Related Videos

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS08:38

Quantification of the Immunosuppressant Tacrolimus on Dried Blood Spots Using LC-MS/MS

Published on: November 8, 2015

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients18:48

In Vitro and In Vivo Assessment of T, B and Myeloid Cells Suppressive Activity and Humoral Responses from Transplant Recipients

Published on: August 12, 2017

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...
Kidney Transplant I: Introduction01:28

Kidney Transplant I: Introduction

A kidney transplant is a surgical approach that involves replacing a non-functioning kidney with a healthy one from a donor. This procedure is often a treatment option for end-stage renal disease (ESRD) patients. The method requires careful recipient selection, including evaluating various medical and psychosocial factors. These criteria vary between transplant centers but generally include assessments of the patient's overall health, adherence to medical recommendations, and lifestyle...
Kidney Transplant II: Surgical Procedure01:26

Kidney Transplant II: Surgical Procedure

Preoperative ManagementThe primary goals of preoperative management in kidney transplantation are to optimize the patient’s metabolic state and prepare them for surgery through diet adjustments, necessary dialysis, and tailored medical treatment. This phase also involves comprehensive infection screening and patient education about the surgical procedure and postoperative care to improve outcomes and adherence.Medical ManagementA comprehensive evaluation is required for both the living donor...
Kidney Transplant III: Nursing Management01:16

Kidney Transplant III: Nursing Management

Postoperative Nursing Management for Kidney Transplant PatientsPostoperative nursing management care includes monitoring the surgical site, encouraging early movement, and promoting lung health through breathing exercises. Nurses also administer prescribed medications like H2-blockers, such as famotidine, or proton pump inhibitors, like omeprazole, to help prevent gastrointestinal ulcers and bleeding. Fungal infections in the mouth and bladder can result from immunosuppressive and antibiotic...